Long-term follow-up of patients with doxorubicin-induced cardiac toxicity after chemotherapy for osteosarcoma

Anti-Cancer Drugs

Volumn 18, Issue 6, 2007, Pages 737-744

  Longhi, Alessandra ^a   Ferrari, Stefano ^a   Bacci, Gaetano ^a   Specchia, Salvatore ^b  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Cardiomyopathy; Chemotherapy; Doxorubicin toxicity; Osteosarcoma

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; SOMATOSTATIN;

ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CARDIOMYOPATHY; CARDIOTOXICITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; FEMALE; FOLLOW UP; HEART GRAFT; HUMAN; INCIDENCE; LONG TERM CARE; MALE; OSTEOSARCOMA; PRIORITY JOURNAL; RISK FACTOR;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CARDIOMYOPATHIES; CHILD; CHILD, PRESCHOOL; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; OSTEOSARCOMA; TREATMENT OUTCOME;

EID: 34548363935     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32803d36fe     Document Type: Article

References (35)

1. US National Cancer Institute. Workshop on Pediatric Oncology. Late Effect of Childhood Cancer Networks. Bethesda: NCI; 2002.
2. Kremer LC, Caron HN. Anthracyclin cardiotoxicity in children. N Engl J Med 2004; 351:120-121.
3. Kremer LC, van Dalen EC, Offringa M, et al. Frequency and risk factors of anthracycline-induced clinical heart failure in children:a systematic review. Ann Oncol 2002; 13:503-512.
4. Kremer LC, van der Pal HJ, Offringa M. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children. A systematic review. Ann Oncol 2002; 13:819-829.
5. Lipshultz SE. Exposure to anthracyclines during childhood causes cardiac injury. Semin Oncol 2006; S,04.019.
6. Sorensen K, Levitt GA, Bull C, et al. Late anthracycline cardiotoxicity after childhood cancer. Cancer 2003; 97:1991-1998.
7. Limat S, Demesmay K, Voillat L, et al. Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma. Ann Oncol 2003; 14:277-281.
8. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91:710-717.
9. Elliott P. Pathogenesis of cardiotoxicity induced by anthracyclines. Semin Oncol 2006; 4 (20 Suppl):2-7.
10. Pein F, Sakiroglu O, Dahan M. cardiac abnormalities 15 years and more after adriamcin therapy in 229 childhood survivors of a solid tumor at the Institute Gustave Roussy. Br J Cancer 2004; 91:37-34.
11. Yeh ET, Tong AT, Lenihan DJ. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 2004; 109:3122-3131.
12. Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol 2002; 13:699-709.
13. Haq MM, Legha SS, Choksi J, et al. Doxorubicine-induced congestive heart failure in adults. Cancer 1985; 56:1361-1365.
14. Ali MK. The natural history of anthracycline cardiotoxicity in children. In: Muggia F, (editor) Cancer Treatment and the Patient. Baltimore: The Johns Hopkins University; 1992: pp. 246-255.
15. Meyers C. Role of iron in anthracycline action. In: Hacker M, Lazo J, editors. Organ directed toxicities of anticancer drugs. Boston: Martinus Nijhoff; 1988. pp. 17-30.
16. Arola OJ, Saraste A, Pulkki K, et al. Acute doxorubicin cardiotoxicity involves cardiomyocyte apopotosis. Cancer Res 2000; 60:1789-1792.
17. Geidel S, Garn M, Gravinghoff L. Cardiomyopathy after osteosarcoma treatment: a contribution to the cardiotoxicity of adriamycin. Klin Padiatr 1991; 203:257-261.
18. Paulides M, Kremers A, Stohr W. Prospective longitudinal evaluation of doxorubicin-induced cardiomyopathy in sarcoma patients: a report of Late Effects Surveillance System (LESS). Ped Blood Cancer 2006; 46:489-495.
19. Bacci G, Picci P, Ruggieri P, et al. Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy for osteosarcoma of the extremities. Cancer 1990; 65:2539-2553.
20. Bacci G, Ferrari S, Bertoni F, et al. Long-term outcome for patients with non metastatic osteosarcoma of the extremity treated at Istituto ortopedico Rizzoli according to IOR/OS2 protocol: an update report. J Clin Oncol 2000; 18:4016-4027.
21. Ferrari S, Mercuri M, Picci P, et al. Non metastatic osteosarcoma of the extremity :results of a neoadjuvant chemotherapy protocol (IOR-OS3) with high dose methotrexate, intraarterial or intravenous cisplatin,doxorubicin and salvage chemotherapy based on histologic tumor response. Tumori 1999; 85:458-464.
22. Bacci G, Ferrari S, Longhi A, et al. Neoadjuvant chemotherapy for high grade osteosarcoma of the extremities: long term results for patients treated according to the Rizzoli IOR OS 3b protocol. J Chem 2001; 13:193-199.
23. Bacci G, Briccoli A, Ferrari S, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli's 4th protocol. Eur J Cancer 2001; 37:2030-2039.
24. Bacci G, Ferrari S, Longhi A, et al. High dose ifosfamide in combination with high dose metotrexate, adryamicin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of ISG/SSG Pilot study. J Chemotherapy 2002; 14:198-206.
25. Ferrari S, Smeland S, Mercuri M. Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol 2005; 23:8845-8852. Epub 2005 Oct 24.
26. Hryniuk WM, Goodyear M. The calculation of received dose intensity. J Clin Oncol 1990; 8:1935-1937.
27. Pellegrini R. Di Bella's method of curing cancer is becoming popular in Italy. BMJ 1998; 317:352.
28. Ward KM, Binns H, Chin C. Pediatric heart transplantation for anthracycline cardiomyopathy: cancer recurrence is rare. J Heart Lung Transplant 2004; 23:1040-1045.
29. Lipshultz SE, Lipsitz SR. Female sex and drug dose as risk factors for late cardiotoxic effect of doxorubicin therapy for childhood cancer. N Engl J Med 1995; 332:1738-1743.
30. Krischer JP, Epstein S, Cuthbertson DD, et al. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group Experience. J Clin Oncol 1997; 15:1544-1552.
31. Casper ES, Gaynor JJ, Hajdu SI, Magill GB, Tan C, Friedrich C, Brennan MF. A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognosticfactors. Cancer 1991; 68:1221-1229.
32. Legha SS, Benjamin RS, Mackay B. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982; 96:133-139.
33. Pratt CB, Ransom JL, Evans WE. Age-related adriamycin cardiotoxicity in children. Cancer Treat Rep 1978; 62:1381-1385.
34. Lipshultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukaemia in childhood. N Eng J Med 1991; 12:808-815.
35. Quezado ZM, Wilson WH, Cunnion RE, Parker MM, Reda D, Bryant G, Ognibene FP. High dose Ifosfamide is associated with severe reversible cardiac disfunction. Ann Intern Med 1993; 118:31-36.